Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, Meagher NS, Na R, Antoniou AC, Brand AH, Kennedy CJ, Nevins N, Pharoah PDP, Shvetsov YB, Winham SJ, Alsop J, Beckmann MW, Bolithon A, Boros J, Bowtell DDL, Brenton JD, Carney ME, Chudecka-Głaz A, Cook LS, Cybulski C, Fasching PA, Fereday S, Fortner RT, García MJ, Goode EL, Goodman MT, Gronwald J, Hartmann A, Hernandez BY, Høgdall E, Huntsman DG, Jensen A, Jimenez-Linan M, Joseph JM, Karlan BY, Kaznowska E, Kjaer SK, Kluz T, Koziak JM, Lester J, Longacre TA, Lycke M, McGuire V, Moysich KB, Murphy RA, Orsulic S, Ramus SJ, Rodríguez-Antona C, Rothstein JH, Samra S, Sieh W, Steed H, Sundfeldt K, Talhouk A, Uciński J, Wang C, Wentzensen N, Whittemore AS, Wilkens LR, Songer T, Brooks MM, Tang L, Modugno F.
Fu Z, et al. Among authors: lester j.
Gynecol Oncol. 2025 Jun 5;198:112-129. doi: 10.1016/j.ygyno.2025.05.013. Online ahead of print.
Gynecol Oncol. 2025.
PMID: 40482607